skin-diseases-and-microbiology-2016_keynote

6 / 6

Volume 4, Issue 7(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Skin Diseases & Microbiology 2016
October 03-05, 2016
Page 33
Notes:
conferenceseries.com
Infectious Diseases, Diagnostic Microbiology &
Dermatologists Summit on Skin Infections
October 03-05, 2016 Vancouver, Canada
International Conference on
Anew approach in preventing hypertrophic scarring/keloid
Wound healing outcome is regulated by a fine balance between deposition and degradation of extracellular matrix
(ECM). Over healing formation such as keloid is mediated by exaggerated ECM deposition and abnormalities in ECM
degradation. Current treatment modalities for prevention of keloid and hypertrophic scarring have limited efficacy, which
raised a great need for innovation within wound care industry. Moving toward novel approaches to prevent these devastating
conditions, we identified the anti-scarring properties of Kynurenic acid (KynA), a naturally occurring small molecule generated
from tryptophan degradation. To slow down/prevent keloid and hypertrophic scar formation, we have delivered KynA within
the wounds before and/or during epithelialization by using either topical application of KynA containing cream or KynA
slow releasing dressing. The results showed a significant outcome improvement in a fibrotic rabbit ear model received this
therapeutic agent. During the course of this talk, the challenges associated with dermal fibrosis will be presented, the reason
for choosing KynA as a potent anti fibrogenic factor will be discussed, in vitro data on efficacy of KynA as an ECMmodulating
factor in favor of improving the wound healing outcome will be presented, the benefit of using KynA in a topical cream and
slow releasing dressing on a fibrotic rabbit ear model will be shown, finally the safety result of KynA cream in a phase 1 clinical
trial will be presented. At the end, the conclusion and the future direction of using KynA as a potent anti-fibrogenic factor for
treatment of keloid and hypertrophic scarring will be presented.
Biography
Aziz Ghahary, PhD and Professor, is the Director of the BC Professional Firefighters ‘Burn and Wound Healing Research Group and has published more than 168
peer-reviewed articles some of which directly related to autoimmune diseases such as type I diabetes. He has been awarded more than 50 research grants from
different local, national and international granting agencies. He is the leading investigator in identifying a serum 14-3-3 eta protein as a biomarker for early detection
of RA and psoriatic RA and this test has now been launched by the Quest Diagnosis and Lifelab in US and Canada, respectively. Finally, he recently identified a
small molecular with anti-scaring properties, which has now been approved by the Health Canada and the Vancouver General Hospital Ethic Committee to proceed
to Phase 1 Clinical Trial.
Aziz Ghahary
University of British Columbia, Canada
Aziz Ghahary, J Infect Dis Ther 2016, 4:7(Suppl)